Clinical trials: Ischemia, Brain
Ischemic Stroke
THE IMPACT- 24M TRIAL (IMPlant Augmenting Cerebral Blood Flow in Mild Strokes Trial 24 Hours From Stroke Onset)
Study Population: Subjects with Mild Acute Ischemic Stroke in the anterior circulation within 24 hours from onset. Study objectives: 1. Identify the personal stimulation level for each patient based on physiological biomarkers 2.
- Trial name
- ImpACT-24M (NCT03551093)
- Testing
- ISS SPG stimulation
- Where
- 4 sites in Georgia
- Volunteers
- 50 people
- Sponsor
- BrainsGate
Ischemic Stroke
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants
This study is a randomized, double-blind, placebo-controlled clinical trial featuring both single ascending dose (SAD), food effect and multiple ascending dose (MAD) phases intended to evaluate the safety, tolerability, PK, PD…
- Trial name
- NCT07371455
- Testing
- LWP779
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Longwood Pharmaceuticals (Hangzhou) Co., Ltd.
Intracranial Aneurysm, Stroke, Ischemic
Neurovascular Product Surveillance Registry
Post market surveillance registry
- Trial name
- INSPIRE (NCT02988128)
- Testing
- Treatment for intracranial aneurysms, Treatment for Acute Ischemic Stroke
- Where
- 99 sites in Argentina, Australia and 22 more
- Volunteers
- 4,000 people
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Stroke, Acute
A Phase 4 Clinical Study to Investigate the Efficacy and Safety of Naloxone HCI IV in Patients With Stroke
This clinical trial was planned for the purpose to re-evaluate the safety and efficacy of naloxone hydrochloride in ischemic cerebral nerve disorders caused by stroke and cerebral hemorrhage.
- Trial name
- NCT05301712
- Testing
- Naloxone hydrochloride 5.0mg/5ml, Sodium Chloride 45mg/5ml
- Where
- South Korea
- Volunteers
- 446 people
- Sponsor
- Samjin Pharmaceutical Co., Ltd.
Acute Ischemic Stroke
The Vesalio NeVa Stent Retriever Study for Treatment of Large Vessel Occlusion Strokes
A prospective, open label, single-arm 90-day study designed to assess the safety, performance and efficacy of thrombus removal in subjects presenting with acute ischemic stroke with the NeVa stent retrievers.
- Trial name
- NCT03927001
- Testing
- NeVa Stent Retrievers
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Vesalio
Diabetes Mellitus Type 2, Cardiovascular Diseases
PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG
To evaluate the proportion of diabetic mellitus patients with CV events as measured by HEMOTAG.
- Conditions
- Diabetes Mellitus Type 2, Cardiovascular Diseases, Coronary Artery Disease, Cerebrovascular Disease
- Trial name
- PRIZETAG (NCT06567795)
- Testing
- Hemotag
- Where
- United States
- Volunteers
- 189 people
- Sponsor
- Aventusoft, LLC.
Dysphagia, Stroke
Reduction of Aspiration Through Cohesive Thin Liquids (CTL) in Patients With Mild Oropharyngeal Dysphagia
The aim of the trial is to identify any systematic effect of cohesiveness on the efficacy of swallowing in patients having dysphagia problems.
- Trial name
- NCT02522351
- Testing
- Cereal extract concentration 1, Cereal extract concentration 2, Cereal extract concentration 3
- Where
- 2 sites in Belgium, France
- Volunteers
- 35 people
- Sponsor
- Société des Produits Nestlé (SPN)
Stroke
Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;
The present study is to be conducted based on the AIS patient data collected from CNSR I, II, and III. The primary objectives are: To investigate the temporal changes in the proportion of intravenous recombinant plasminogen…
- Trial name
- NCT04290494
- Testing
- IV rtPA (intravenous recombinant plasminogen activator)
- Where
- China
- Volunteers
- 42,188 people
- Sponsor
- Boehringer Ingelheim
Atherosclerotic Cardiovascular Disease
In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
Study CKJX839B1FR01 in an In silico trial to predict the efficacy of Inclisiran therapy on major adverse cardiovascular events (MACE) and cardiovascular (CV) death in virtual patients with atherosclerotic cardiovascular disease…
- Trial name
- SIRIUS (NCT05974345)
- Testing
- Inclisiran sodium, Ezetimibe, Evolocumab
- Where
- France
- Volunteers
- 204,691 people
- Sponsor
- Novartis Pharmaceuticals
Acute Ischemic Stroke
REVascularization In Large VEssel Occlusion for Acute Ischemic Stroke
The objective of this study is to evaluate the safety and effectiveness of the SOFIA Flow 88 Aspiration Catheter for treatment of acute ischemic stroke.
- Trial name
- REVIVE (NCT07216170)
- Testing
- SOFIA Flow 88 Aspiration Catheter
- Volunteers
- 200 people
- Sponsor
- Microvention-Terumo, Inc.
Acute Ischemic Stroke
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
The primary objective of the study is to assess the clinical effects of natalizumab versus placebo in acute ischemic stroke on clinical measures of functional independence and activities of daily living.
- Trial name
- ACTION2 (NCT02730455)
- Testing
- natalizumab
- Where
- 53 sites in United States, Germany and 2 more
- Volunteers
- 277 people
- Sponsor
- Biogen
Stroke, Ischemic
A Phase Ⅱb Study of XY03-EA Tablets in Acute Ischemic Stroke
This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase Ⅱb/Ⅲ clinical study to evaluate the efficacy and safety of XY03-EA tablets, a novel oral neuroprotective agent, and explore the…
- Trial name
- XY03-EA (NCT06755944)
- Testing
- XY03-EA 150 mg (per dose), XY03-EA 300 mg (Regimen A), XY03-EA 300 mg (Regimen B)
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Shijiazhuang Yiling Pharmaceutical Co. Ltd
Atrial Fibrillation, Ischemic Stroke
AMPLATZER Cardiac Plug Clinical Trial
The objective of this study is to evaluate the safety and effectiveness of the ACP in subjects with nonvalvular atrial fibrillation by demonstrating that the device is non-inferior to optimal medical therapy (OMT) with respect to…
- Conditions
- Atrial Fibrillation, Ischemic Stroke, Peripheral Thromboembolism
- Trial name
- NCT01118299
- Testing
- AMPLATZER Cardiac Plug
- Where
- 18 sites in United States
- Volunteers
- 97 people
- Sponsor
- Abbott Medical Devices
Atrial Fibrillation
Evaluation of the Next Generation WATCHMAN LAA Closure Technology in Non-Valvular AF Patients (EVOLVE)
This study will evaluate the next generation WATCHMAN Left Atrial Appendage (LAA) Closure Device as implanted in patients with non-valvular atrial fibrillation (AF) with a CHADS2 stroke risk stratification score of 1 or greater.
- Trial name
- EVOLVE (NCT01196897)
- Testing
- WATCHMAN LAA Closure Technology (Gen 4.0)
- Where
- 3 sites in Czechia, Germany
- Volunteers
- 69 people
- Sponsor
- Boston Scientific Corporation
Acute Ischemic Stroke
A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic Stroke
The study is a prospective, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of tirofiban in combination with intravenous thrombolytic therapy with alteplase in acute ischemic…
- Trial name
- RESET (NCT05188417)
- Testing
- Tirofiban 0.05 MG/ML, 0.9% sodium chloride solution
- Where
- China
- Volunteers
- 266 people
- Sponsor
- GrandPharma (China) Co., Ltd.
Post-Ischemic Stroke
A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.
The objective of this study is to determine the effect of two dose strengths of dalfampridine-Extended Release (ER) tablets, taken twice daily for 12 weeks, on stable walking deficits in subjects with post-ischemic stroke.
- Trial name
- MILESTONE℠ (NCT02271217)
- Testing
- dalfampridine-ER 7.5mg, dalfampridine-ER 10mg
- Where
- 74 sites in United States, Canada
- Volunteers
- 377 people
- Sponsor
- Acorda Therapeutics
Arterial Ischemic Stroke
A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)
The primary study objective is to assess the safety of afamelanotide while the secondary objective is to assess whether the therapy affects the size of the penumbra, by increasing blood flow, restoring oxygen supply to the brain…
- Trial name
- NCT04962503
- Testing
- Afamelanotide
- Where
- Australia
- Volunteers
- 6 people
- Sponsor
- Clinuvel Pharmaceuticals Limited
Acute Ischemic Stroke
Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study designed to evaluate the efficacy of recombinant human tissue-type plasminogen activator variant (rhTNK-tPA) (0.25 mg/kg, maximum dose…
- Trial name
- TRACE-LATE (NCT07201688)
- Testing
- rhTNK-tPA
- Where
- China
- Volunteers
- 890 people
- Sponsor
- CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
Ischemic Stroke
European Registry on the ACE Reperfusion Catheters and the Penumbra System in the Treatment of Acute Ischemic Stroke
Prospective, single-arm, multicenter, observational registry of the ACE Reperfusion Catheters and the Penumbra System in Europe.
- Trial name
- PROMISE (NCT02678169)
- Testing
- Penumbra Aspiration System
- Where
- Germany
- Volunteers
- 204 people
- Sponsor
- Penumbra Inc.
Cerebral Infarction
Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke
This study is randomized, Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) controlled study on acute ischemic stroke. The primary endpoints were the rate of patients with modified Rankin Scale score of 0-1 at 3 months.
- Trial name
- NCT00200356
- Testing
- Edaravone, Sodium Ozagrel
- Volunteers
- 401 people
- Sponsor
- Shionogi